text.skipToContent text.skipToNavigation

Maintenance Notice in CEST time zone (1:00 - 4:00 AM April 19, 2026): The website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.

Published TCIMAIL newest issue No.201

Luxembourg

English

My Account

Orders

Quick Order Form

Quotes

Saved Carts

Account Details

Sign Out
Sign In
- Sign in
- Register
€0.00

- Sign in
- Register

Published TCIMAIL newest issue No.201

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 2207-75-2 | Product Number: O0164

Potassium Oxonate

Purity: >98.0%(T)(HPLC)

Synonyms:

Allantoxanic Acid Potassium Salt
Oxonic Acid Potassium Salt
Potassium Allantoxanate
Potassium 4,6-Dihydroxy-1,3,5-triazine-2-carboxylate

Product Documents:

Size	Unit Price	Belgium	Japan*	Quantity	Shipping Information
5G	€24.00	Contact Us	Contact Us		Shipping Simulation
25G	€76.00	2	≥100		Shipping Simulation

* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)

Added to Your Shopping Cart

General Information plus

Specifications & Properties plus

Specifications

Appearance	White to Almost white powder to crystal
Purity(HPLC)	min. 98.0 area%
Purity(Nonaqueous Titration)	min. 98.0 %

Properties (reference)

Melting Point

300 °C

Safety & Regulations plus

GHS

Related Laws:

EC Number	218-627-5
RTECS#	RR4580000

Transport Information:

HS Number

2933698090

Applications & Literature plus

Application

Potassium Oxonate: An Inhibitor of Orotate Phosphoribosyltransferase (OPRT)

Potassium oxonate is an inhibitor of orotate phosphoribosyltransferase (OPRT) that is an enzyme involved in the biosynthesis of pyrimidine nucleotides and catalyzes the phosphorylation of 5-FU [F0151] to an active metabolite 5-fluorouridine-5'-monophosphate (FUMP). The gastrointestinal toxicity (GIT) of the oral administration of 5-FU is also caused by the phosphorylation by OPRT in the gut wall. Potassium oxonate selectively and competitively inhibits OPRT. As a result, 5-FU associated gastrointestinal toxic effects are reduced. Potassium oxonate is often used as combined agents to enhance the antitumor activity of fluoropyrimidines, such as S-1 (tegafur [F0635] a prodrug of 5-FU, gimeracil [C2243] and potassium oxonate at a molar ratio of 1:0.4:1). (The product is for research purpose only.)

References

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- T. Shirasaka, Y. Shimamato, H. Ohshimo, M. Yamaguchi, T. Kato, K. Yonekura, M. Fukushima, Anti-Cancer Drugs 1996, 7, 548.
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- T. Shirasaka, K. Nakano, T. Takechi, H. Satake, J. Uchida, A. Fujioka, H. Saito, H. Okabe, K. Oyama, S. Takeda, N. Unemi, M. Fukushima. Cancer Res. 1996, 56, 2602.
Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats
- K. Yoshisue, H. Masuda, E. Matsushima, K. Ikeda, S. Nagayama, Y. Kawaguchi, Drug Metab. Dispos. 2000, 28, 1162.
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
- K. Yoshisue, K. Hironaga, S. Yamaguchi, A. Yamamoto, S. Nagayama, Y. Kawaguchi, Cancer Chemother. Pharmacol. 2000, 46, 51.
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
- T. Yamashita, Y. Ueda, N. Fuji, T. Itoh, H. Kurioka, T. Shirasaka, H. Yamagishi, Cancer Chemother. Pharmacol. 2006, 58, 183.

Application

Reagent for hyperuricemia (gout) model

References

Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
- Y. Osada, M. Tsuchimoto, H. Fukushima, K. Takahashi, S. Kondo, M. Hasegawa, K. Komoriya, Eur. J. Pharmacol. 1993, 241, 183.
Hyperuricemia induced by some antihypertensives and uricosuric drugs in oxonate-treated rats
- Y. Yonetani, M. Ishii, K. Iwaki, Jpn. J. Pharmacol. 1980, 30, 829.
Use of the uricase-inhibited rat as an animal model in toxicology
- B. Stavric, E. A. Nera., Clin. Toxicol. 1978, 13, 47.
Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice
- Y. S. Chen, Q. H. Hu, X. Zhang, Q. Zhu, L. D. Kong, Pharmacology 2013, 92, 75.

PubMed Literature

Documents

Bulk Pharmaceutical Agents & Intermediates for Pharmaceuticals

Reagents for Preparing Animal Disease Models

Product Articles

Product Documents (Note: Some products will not have analytical charts available.)

Safety Data Sheet (SDS)

Language

Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications

C of A & Other Certificates

Type

Lot Number

Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

Sample C of A

This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts

Lot Number

Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

Product Categories

Life Science

Biochemicals and Reagents

Animal Disease Models Preparation

Reagents for Life-style related Disease Models

Chemicals by Class

Chemistry

Building Blocks

Heterocyclic Building Blocks

Non-Halogenated Heterocyclic Building Blocks

Triazines [Non-Halogenated Heterocyclic Building Blocks]

Life Science

Biochemicals and Reagents

Animal Disease Models Preparation

Reagents for Life-style related Disease Models

Chemicals by Class

Chemistry

Building Blocks

Heterocyclic Building Blocks

Non-Halogenated Heterocyclic Building Blocks

Triazines [Non-Halogenated Heterocyclic Building Blocks]

Product Number	O0164
Purity / Analysis Method	>98.0%(T)(HPLC)
Molecular Formula / Molecular Weight	C__4H__2KN__3O__4 = 195.18
Physical State (20 deg.C)	Solid
Storage Temperature	Room Temperature (Recommended in a cool and dark place, <15°C)
CAS RN	2207-75-2
Related CAS RN	937-13-3
Reaxys Registry Number	4049961
PubChem Substance ID	87574167
MDL Number	MFCD00010565

Americas

Europe

Asia Pacific

Africa & Middle East

CAS RN: 2207-75-2 | Product Number: O0164

Potassium Oxonate

References

References

Documents

Safety Data Sheet (SDS)

Specifications

C of A & Other Certificates

Sample C of A

Analytical Charts

Other Documents

Product Categories

Life Science

Chemicals by Class

Chemistry

Life Science

Chemicals by Class

Chemistry

About TCI

How To Order

Select Country or Region & Language

Americas

Europe

Asia Pacific

Africa & Middle East

CAS RN: 2207-75-2 | Product Number: O0164

Potassium Oxonate

References

References

Documents

Safety Data Sheet (SDS)

Specifications

C of A & Other Certificates

Sample C of A

Analytical Charts

Other Documents

Product Categories

Life Science

Chemicals by Class

Chemistry

Life Science

Chemicals by Class

Chemistry